Sanofi (Sanofi) EV-to-Revenue

: 2.49 (As of Today)

View and export this data going back to 2002. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sanofi's enterprise value is $125,962 Mil. Sanofi's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $50,495 Mil. Therefore, Sanofi's EV-to-Revenue for today is 2.49.

The historical rank and industry rank for Sanofi's EV-to-Revenue or its related term are showing as below:

SNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.35 Med: 3.16 Max: 4.34
Current: 2.49

During the past 13 years, the highest EV-to-Revenue of Sanofi was 4.34. The lowest was 2.35. And the median was 3.16.

SNY's EV-to-Revenue is ranked worse than
52.88% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.33 vs SNY: 2.49

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-20), Sanofi's stock price is $46.29. Sanofi's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $20.14. Therefore, Sanofi's PS Ratio for today is 2.30.

Sanofi EV-to-Revenue Historical Data

The historical data trend for Sanofi's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

3.40

2.93

3.11

2.68

2.63

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue																3.11	-	2.68	-	2.63

Competitive Comparison

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-Revenue falls into.

Sanofi EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sanofi's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	125962.355	/	50495.034
	=	2.49

Sanofi's current Enterprise Value is $125,962 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $50,495 Mil.

Sanofi (NAS:SNY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sanofi's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	46.29	/	20.144
	=	2.30

Sanofi's share price for today is $46.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $20.14.

Sanofi EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sanofi's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.